Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.
Journal
The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
11
05
2020
revised:
21
05
2020
accepted:
21
05
2020
pubmed:
31
5
2020
medline:
1
8
2020
entrez:
31
5
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and no proven treatments are available. Convalescent plasma therapy has been used with varying degrees of success to treat severe microbial infections for >100 years. Patients (n = 25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28, 2020, to April 14, 2020. Patients were transfused with convalescent plasma, obtained from donors with confirmed severe acute respiratory syndrome coronavirus 2 infection who had recovered. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 after transfusion. Clinical improvement was assessed on the basis of a modified World Health Organization six-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains. At day 7 after transfusion with convalescent plasma, nine patients had at least a one-point improvement in clinical scale, and seven of those were discharged. By day 14 after transfusion, 19 (76%) patients had at least a one-point improvement in clinical status, and 11 were discharged. No adverse events as a result of plasma transfusion were observed. Whole genome sequencing data did not identify a strain genotype-disease severity correlation. The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.
Identifiants
pubmed: 32473109
pii: S0002-9440(20)30257-1
doi: 10.1016/j.ajpath.2020.05.014
pmc: PMC7251400
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1680-1690Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00050
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI139369
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI146771
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Références
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
J Med Virol. 2020 Sep;92(9):1386-1390
pubmed: 32311094
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267
pubmed: 32209890
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Swiss Med Wkly. 2020 Feb 27;150(9-10):
pubmed: 32227799
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):311-315
pubmed: 32298982
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
J Crit Care. 2020 Aug;58:29-33
pubmed: 32330817
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855